GW two additional programs - blockbuster obesity drug?
If GW is targeting diabetes it derivative study should be obesity prevention drugs. No other obesity pills have been FDA approved in US market use since Phen-phen which was disaster - heart attacks. Two companies who is in obesity cure is VVUS and ARNA, on speculation investors bid companys market share to over $1B in the last few months. One can only imagine if GW is successful in obesity drug (mentioned in company website study since 2007) the market cap easily in several billions. GW holds patents programmable inhibitors Nabiximols is a patented cannabinoid oromucosal mouth spray"USPTO: Not only does GW have claims directed to the method of sublingual delivery of the Sativex formulation, but it also has claims directed to the device within which it is contained," Gover added. "In total, we now have seven different patent families containing one or more pending or issued patents relating to Sativex." The issued patent is expected to expire in March 2021.
Target price tripled might be convervative since two additional programs were not factored in.
GW has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and two additional programs expected to advance into Phase 1 and Phase 2 clinical trials in the next 12 months.
Appetite suppression is a tricky area. Inhibiting a normal body function could result in unintended consequences. Obesity is almost always a lifestyle issue. Besides, there are more inflammatory diseases than you can count and cannabidiol reduces inflammation.